StreetAlpha.app
Home › Stocks › COGT

Cogent Biosciences, Inc. (COGT)

Healthcare
$27.85
▲ +1.49%
LAST CLOSE · NOV 17

Cogent Biosciences develops targeted drugs for rare, genetically driven diseases, led by bezuclastinib for systemic mastocytosis and GIST. It last closed at $27.85 on Nov 17, up 1.49% on the day. The average 12-month price target from 2 analysts is $55.50 (+99.3% from the last close), with a high of $56.00 and a low of $55.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in COGT, 0% of them bullish and 100% bearish. In the past 30 days there were 2 dark pool prints totaling $2.3M, the largest $1.6M.

AI Auto Pilots
Is COGT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$407.7M
EPS (diluted)
−$2.26
Free cash flow
−$325.8M
Valuation
Market cap
$4.8B
174.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$217.5M
At Sep 30
Debt
$223.7M
At Sep 30
Shareholder equity
$516.3M
Shares outstanding
174.0M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$72.3M−$72.3MFY2021FY2022: −$140.2M−$140.2MFY2022FY2023: −$192.4M−$192.4MFY2023FY2024: −$255.9M−$255.9MFY2024FY2025: −$328.9M−$328.9MFY2025

From COGT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated COGT in the past 90 days, not enough for a consensus
Average 12-month target
$55.50
▲ 99.3% upside

Based on 2 analysts who set a price target on COGT in the past 90 days. The average target is $55.50, with a high of $56.00 and a low of $55.00, compared with the last close of $27.85.

Low $55.00Avg $55.50High $56.00
Blue marker: last close $27.85
Highest target$56.00
Average target$55.50
Lowest target$55.00
Latest rating changes
HC Wainwright & Co.Target raised
Nov 9Buy$55 → $56
WedbushReiterated
Sep 16Buy$55
HC Wainwright & Co.Reiterated
Sep 15Buy$55
Piper SandlerMaintained
Aug 17Buy$55
GuggenheimMaintained
Aug 12Buy$52
DateFirmActionRatingPrice target
Nov 9HC Wainwright & Co.Target raisedBuy$55 → $56
Sep 16WedbushReiteratedBuy$55
Sep 15HC Wainwright & Co.ReiteratedBuy$55
Aug 17Piper SandlerMaintainedBuy$55
Aug 12GuggenheimMaintainedBuy$52
Loading…

Technical Analysis

COGT · as of the Nov 17 close · updated after every close
Downtrend

The stock is 10% below its 20 day and 12% below its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the swing low (Oct 14) at $27.74, and the nearest resistance the Pivot R1 at $28.50.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 6.0%/day
Key levels
$43.7352 week high+57.0%
$35.21200 day average+26.4%
$34.77100 day average+24.8%
$31.1050 day average+11.7%
$31.07Swing high (Oct 12)+11.6%
$30.6620 day average+10.1%
$28.50Pivot R1+2.3%
$27.85Last close
$27.74Swing low (Oct 14)−0.4%
$27.43Pivot−1.5%
$26.78Pivot S1−3.8%
$26.3652 week low−5.4%
Indicators
RSI (14)39.42Weak, oversold below 30Neutral
MACD-0.76Below its signal lineBearish
Stochastic8.2Near the bottom of its rangeOversold
ADX (14)19.1No clear trend
Williams %R-80.6Oversold below −80, overbought above −20Oversold
CCI (20)-194.1Oversold below −100, overbought above 100Oversold
Rate of change−10.3%Change over 10 sessionsBearish
ATR (14)$1.66Typical daily range, 6.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for COGT

What happened before

See how COGT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow COGT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How COGT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 13 – Oct 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.3M
Largest print
$1.6M
Loading…

COGT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲184 buying vs 149 selling
  • ▲Held by funds +0.7 pts
  • ▼Funds holding -10
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding317327−3.1%
In funds' top 1015150.0%
Held by funds115.2%114.5%+0.7 pts
New / increased51 / 13364 / 137−8.5%
Reduced / sold out90 / 5984 / 47+13.7%
Put/call ratio0.050.15−66.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See COGT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COGT is in one of them and how their past COGT trades turned out.

COGT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered COGT in an article yet. Here's the latest on the wider market.

COGT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 20
Who traded COGT · since 2022
Latest 1 filing
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYBuy$1K – $15KDec 12, 2022Jan 20, 202339 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Cogent Biosciences

Cogent Biosciences is a biotechnology company based in Waltham, Massachusetts, that develops drugs for diseases caused by specific genetic mutations. Its lead candidate, bezuclastinib, is being studied for systemic mastocytosis, a rare disease in which mast cells build up in the body, and for gastrointestinal stromal tumors, a cancer of the digestive tract. The company is also developing other targeted therapies, including inhibitors aimed at FGFR2/3 and ErbB2 mutations. Its intended patients are people with rare, genetically driven diseases.

Headquarters
Waltham, MA